Trials / Recruiting
RecruitingNCT07252414
GenSci143 in Participants With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors
Detailed description
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GenSci143 for injection | GenSci143 for injection, administered Q3W, with a dosage ranging from 0.5mg/kg to 4.5mg/kg. |
Timeline
- Start date
- 2025-12-20
- Primary completion
- 2028-10-30
- Completion
- 2029-06-30
- First posted
- 2025-11-26
- Last updated
- 2026-01-05
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07252414. Inclusion in this directory is not an endorsement.